IN2014CN04482A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04482A
IN2014CN04482A IN4482CHN2014A IN2014CN04482A IN 2014CN04482 A IN2014CN04482 A IN 2014CN04482A IN 4482CHN2014 A IN4482CHN2014 A IN 4482CHN2014A IN 2014CN04482 A IN2014CN04482 A IN 2014CN04482A
Authority
IN
India
Prior art keywords
polypeptide
integrin
modified polypeptide
affinity
drugs
Prior art date
Application number
Other languages
English (en)
Inventor
Hanmei Xu
Haimin Chang
Zhian Kang
Original Assignee
Hanmei Xu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmei Xu filed Critical Hanmei Xu
Publication of IN2014CN04482A publication Critical patent/IN2014CN04482A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02Peptides being immobilised on, or in, an organic carrier
    • C07K17/04Peptides being immobilised on, or in, an organic carrier entrapped within the carrier, e.g. gel, hollow fibre
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02Peptides being immobilised on, or in, an organic carrier
    • C07K17/08Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IN4482CHN2014 2011-11-21 2012-11-17 IN2014CN04482A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011103705299A CN102417540A (zh) 2011-11-21 2011-11-21 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
PCT/CN2012/084788 WO2013075600A1 (zh) 2011-11-21 2012-11-17 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用

Publications (1)

Publication Number Publication Date
IN2014CN04482A true IN2014CN04482A (zh) 2015-09-04

Family

ID=45942198

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4482CHN2014 IN2014CN04482A (zh) 2011-11-21 2012-11-17

Country Status (7)

Country Link
US (2) US20140329759A1 (zh)
EP (1) EP2784093B1 (zh)
KR (2) KR20140096373A (zh)
CN (1) CN102417540A (zh)
AU (1) AU2012343020B2 (zh)
IN (1) IN2014CN04482A (zh)
WO (1) WO2013075600A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102417540A (zh) * 2011-11-21 2012-04-18 中国药科大学 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
CN103623394A (zh) * 2013-12-11 2014-03-12 南京安吉生物科技有限公司 一种peg-hm-3和铂类、紫杉醇类或他滨类药物在制备实体瘤药物中的用途
CN103656615B (zh) * 2013-12-11 2017-01-04 南京安吉生物科技有限公司 一种hm-3和铂类、紫杉醇类或他滨类药物在制备实体瘤药物中的用途
CN103739673B (zh) * 2013-12-31 2015-08-19 浙江元太生物科技有限公司 一种聚乙二醇修饰的抑制白介素-6多肽及其应用
CN103739671B (zh) * 2013-12-31 2015-08-26 郭向华 一种聚乙二醇修饰的抑制核因子-κB多肽及其应用
CN103739669B (zh) * 2013-12-31 2015-08-26 浙江元太生物科技有限公司 一种抑制白介素-6多肽及其应用
CN103720667B (zh) * 2014-01-09 2016-04-13 中国药科大学 Ap-25多肽冻干粉针制剂及其制备方法和用途
CN103736078B (zh) * 2014-01-09 2017-12-12 南京安吉生物科技有限公司 mPEG‑HM‑3多肽冻干粉针制剂及其制备方法和用途
CN103819542A (zh) * 2014-02-28 2014-05-28 中国药科大学 一种聚乙二醇修饰及蛋白质融合表达的整合素阻断剂ap-25及其应用
CN104127378A (zh) * 2014-08-11 2014-11-05 中国药科大学 mPEG-SC20K-HM-3多肽注射液及其制备方法和用途
CN105622721A (zh) * 2015-12-16 2016-06-01 李斯文 一种聚乙二醇修饰的血管生成抑制剂hs-1及其应用
CN105646667A (zh) * 2016-04-06 2016-06-08 南京安吉生物科技有限公司 聚乙二醇修饰的血管生成抑制剂hm-1及其应用
CN108623693B (zh) * 2017-03-20 2022-03-25 徐寒梅 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用
CN109503700A (zh) * 2017-09-14 2019-03-22 南京安吉生物科技有限公司 马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
CN107857800B (zh) * 2017-11-09 2020-05-05 北京赛升药业股份有限公司 一种长效整合素抑制剂及其应用
CN109879969B (zh) * 2017-12-06 2024-04-09 天士力生物医药股份有限公司 一种hm-3融合蛋白及其应用
CN111855876B (zh) * 2020-07-10 2023-05-02 北京赛升药业股份有限公司 一种安替安吉肽有关物质的检测方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
NZ540363A (en) * 2002-11-25 2007-11-30 Attenuon Llc Peptides which target tumor and endothelial cells, compositions and uses thereof
CN1314705C (zh) * 2005-06-03 2007-05-09 中国药科大学 高效抑制血管生成多肽及其制备方法和应用
KR100863060B1 (ko) * 2006-06-02 2008-10-10 베이징 선바이오 바이오테크, 코오퍼레이션, 리미티드 암 억제 활동을 하는 재조합 단백질, 그 암호화 유전자 및 재조합 단백질을 활성성분으로 포함하는 암치료용 약학적 조성물
CN102145161A (zh) * 2011-04-07 2011-08-10 中国药科大学 整合素阻断剂在制备治疗肿瘤药物中的应用
CN102178656B (zh) * 2011-05-12 2012-08-22 内蒙古奇特生物高科技(集团)有限公司 Hm-3多肽冻干粉制剂及其制备方法
CN102205110B (zh) * 2011-05-18 2014-03-26 中国药科大学 整合素阻断剂在制备治疗新生血管性眼病药物中的应用
CN102417540A (zh) * 2011-11-21 2012-04-18 中国药科大学 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
CN104127378A (zh) * 2014-08-11 2014-11-05 中国药科大学 mPEG-SC20K-HM-3多肽注射液及其制备方法和用途

Also Published As

Publication number Publication date
KR102106485B1 (ko) 2020-05-04
US20170100489A1 (en) 2017-04-13
EP2784093A4 (en) 2015-08-05
KR20140096373A (ko) 2014-08-05
WO2013075600A1 (zh) 2013-05-30
EP2784093A1 (en) 2014-10-01
EP2784093B1 (en) 2019-10-09
US20140329759A1 (en) 2014-11-06
AU2012343020A1 (en) 2014-06-12
AU2012343020B2 (en) 2016-05-19
KR20190090872A (ko) 2019-08-02
CN102417540A (zh) 2012-04-18

Similar Documents

Publication Publication Date Title
IN2014CN04482A (zh)
HRP20181364T8 (hr) Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci
HK1211467A1 (zh) 的形式,表達 形式的細胞,以及 複合物的治療用途
IN2014DN10889A (zh)
HK1221178A1 (zh) 卡博替尼劑型及其在癌症治療中的使用
MY185016A (en) Progenitor cells of mesodermal lineage
PL2818483T3 (pl) Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
MX2016004678A (es) Composiciones para el tratamiento del cancer.
MX365835B (es) Uso de akkermansia para tratar trastornos metabolicos.
EP2532680A4 (en) MEDICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
IN2014DN09098A (zh)
EP2814509A4 (en) ANTIBODY AGAINST INTEGRIN V6 AND USE THEREOF FOR THE TREATMENT OF CANCER
EA033115B1 (ru) АНТИТЕЛА ПРОТИВ CD38 И СЛИТЫЕ БЕЛКИ С ОСЛАБЛЕННЫМ ИНТЕРФЕРОНОМ АЛЬФА-2b
IL237125A0 (en) Use of preparations containing niclosamide and/or its derivatives for the treatment of solid tumors
IL222382A0 (en) Robo1-fc fusion protein and use thereof for treating tumours
EP2651443A4 (en) ANTI-CCL25 AND ANTI-CCR9 ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CANCER AND THE MIGRATION OF CANCER CELLS
IN2014MN01945A (zh)
MX2012008958A (es) Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
PT2699233T (pt) Material particulado e toxina celular para utilização no tratamento de um tumor sólido
EP2912171A4 (en) NOVEL ESTERASES FOR THE TREATMENT OF CELLULOSIC AND LIGNOCELLULOSIC MATERIALS
IL220092A (en) 44cd monoclonal antibody for use in the treatment of squamous cell carcinoma of the head and neck
EP2651894A4 (en) THIOSEMICARBAZONE COMPOUNDS FOR CANCER TREATMENT
NZ628433A (en) Chitosan-derived compositions
MX2015003343A (es) Tratamiento combinado con el farmaco de interferencia de netrina-1 y el farmaco quimioterapeutico.
RS54961B1 (sr) Farmaceutska kompozicija za lečenje promuklosti ili bolova u grlu